Tag Archives: csl limited share price history csl limited linkedin csl limited careers csl limited asx csl limited employees csl limited aktienkurs csl behring 1010 mobile csl

CSL Limited FDA acceptance of BLA

FDA acceptance of BLA: CSL Limited (ASX: CSL) had announced that the US Food and Drug Administration (FDA) has accepted for review of CSL Behring’s Biologics License Application (BLA) for its low-volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy, CSL830, as prophylaxis to prevent Hereditary Angioedema (HAE) attacks. Moreover, CSL has reported a net profit after tax (NPAT) of

Read more

CSL Limited Weak bottom line drove the stock lower

Weak bottom line drove the stock lower: CSL Limited (ASX: CSL) has announced that the US Food and Drug Administration (FDA) has accepted for review of CSL Behring’s Biologics License Application (BLA) for its low-volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy, CSL830, as prophylaxis to prevent Hereditary Angioedema (HAE) attacks. On the other hand, CSL net profit after

Read more

CSL Ltd.’s Product and regional diversification

Product and regional diversification: CSL Ltd.’s (ASX: CSL) had received FDA approval for AFSTYLA (rFVIII – single chain) and Flucelvax Quadrivalent (influenza vaccine) few months ago. The company also received European commission approval for IDELVION® (rFLX-FP). CSL’s Seqirus is the second largest influenza vaccine provider to the US$6 billion market. Its core business is of blood plasma therapies for a

Read more

CSL Limited Approval For Influenza Vaccine

Approval for Influenza Vaccine: CSL Limited (ASX: CSL) has got approval from US Food and Drug Administration for the Influenza Vaccine FLUCELVAX QUADRIVALENT against the A viruses and B viruses which would further broaden their influenza coverage. CSL has been granted seven years of marketing exclusivity in March 2016 by the U.S. Food and Drug Administration for IDELVION. CSL has

Read more

CSL Limited Global Scale And Unique Business Model

Global scale and unique business model: CSL Ltd (ASX: CSL) is up 4.32% in the last five days (as at April 20, 2016) and has grown in scale to become global leader through organic and acquisition route. The Board has implemented numerous on market share buybacks in recent years, boosting EPS (announced $1 billion on October 2015 while finished 53%

Read more